STX.LSE Shield Therapeutics plc

Healthcare Biotechnology London Exchange
0.0305 GBX
Close of Nov 3, 2026
2.93 12.50
Market cap
GBX 32.8M
P/E
-
P/B
76.33x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is STX.LSE undervalued?

Graham number

The Graham number of Shield Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Shield Therapeutics plc fundamental analysis

No fundamental analysis for Shield Therapeutics plc yet.

Shield Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Shield Therapeutics plc

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

Full company profile